speb/financial-data huggingface dataset:
GENF.L balance_sheet (annual, 2024-12-31) — Taxes Receivable: 31757.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Taxes Receivable: 31757.00
GENF.L balance_sheet (annual, 2024-12-31) — Total Assets: 385908.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Total Assets: 385908.00
GENF.L balance_sheet (annual, 2024-12-31) — Total Capitalization: -403008.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Total Capitalization: -403008.00
GENF.L balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: -403008.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: -403008.00
GENF.L income_statement (annual, 2024-12-31) — Total Expenses: 1587235.00
GENF.L balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 788916.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 788916.00
GENF.L balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 2067.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 2067.00
GENF.L balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
GENF.L income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -1587235.00
GENF.L balance_sheet (annual, 2024-12-31) — Working Capital: -405075.00
GENF.L balance_sheet (quarterly, 2024-12-31) — Working Capital: -405075.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 573297.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 5667921.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Capital Stock: 136064.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 279445.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 279445.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Common Stock: 136064.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Current Assets: 466853.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 771384.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Invested Capital: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Net PPE: 1528.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 453547942.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Other Payable: 185441.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Other Receivables: 83094.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Payables: 758738.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 38708.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -6328718.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Share Issued: 453547942.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 65606.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Total Assets: 468381.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Total Capitalization: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: -303003.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 771384.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 1528.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 0.00
GENF.L balance_sheet (quarterly, 2025-06-30) — Working Capital: -304531.00
GENF.L income_statement (annual, 2025-12-31) — +Operating Expense: 1417564.00
GENF.L income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Accounts Payable: 646660.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 646660.00
GENF.L balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 6095921.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 6095921.00
GENF.L income_statement (annual, 2025-12-31) — Basic Average Shares: 426711928.00
GENF.L income_statement (annual, 2025-12-31) — Basic EPS: 0.00
GENF.L cash_flow (annual, 2025-12-31) — Beginning Cash Position: 278682.00
GENF.L balance_sheet (annual, 2025-12-31) — Capital Stock: 148064.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Capital Stock: 148064.00
GENF.L balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 111792.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 111792.00
GENF.L balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 111792.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 111792.00
GENF.L balance_sheet (annual, 2025-12-31) — Cash Financial: 111792.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Cash Financial: 111792.00
GENF.L cash_flow (annual, 2025-12-31) — Change In Payable: 214255.00
GENF.L cash_flow (annual, 2025-12-31) — Change In Receivables: -234369.00
GENF.L cash_flow (annual, 2025-12-31) — Change In Working Capital: -20114.00
GENF.L cash_flow (annual, 2025-12-31) — Changes In Cash: -127887.00
GENF.L balance_sheet (annual, 2025-12-31) — Common Stock: 148064.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Common Stock: 148064.00
GENF.L balance_sheet (annual, 2025-12-31) — Common Stock Equity: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: -550785.00
GENF.L cash_flow (annual, 2025-12-31) — Common Stock Issuance: 1308698.00
GENF.L balance_sheet (annual, 2025-12-31) — Current Assets: 451320.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Current Assets: 451320.00
GENF.L balance_sheet (annual, 2025-12-31) — Current Liabilities: 1003171.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 1003171.00
GENF.L cash_flow (annual, 2025-12-31) — Depreciation: 1093.00
GENF.L cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 1093.00
GENF.L income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 1093.00
GENF.L income_statement (annual, 2025-12-31) — Depreciation Income Statement: 1093.00
GENF.L income_statement (annual, 2025-12-31) — Diluted Average Shares: 426711928.00
GENF.L income_statement (annual, 2025-12-31) — Diluted EPS: 0.00
GENF.L income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — EBIT: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — EBITDA: -1416471.00
GENF.L cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -39003.00
GENF.L cash_flow (annual, 2025-12-31) — End Cash Position: 111792.00
GENF.L cash_flow (annual, 2025-12-31) — Financing Cash Flow: 1308698.00
GENF.L cash_flow (annual, 2025-12-31) — Free Cash Flow: -1436585.00
GENF.L income_statement (annual, 2025-12-31) — General And Administrative Expense: 404739.00
GENF.L income_statement (annual, 2025-12-31) — Interest Expense: 0.00
GENF.L income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Invested Capital: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Invested Capital: -550785.00
GENF.L cash_flow (annual, 2025-12-31) — Investing Cash Flow: 0.00
GENF.L cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 1308698.00
GENF.L cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 1308698.00
GENF.L income_statement (annual, 2025-12-31) — Net Income: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -1417564.00
GENF.L cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Net Interest Income: 0.00
GENF.L income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Net PPE: 1066.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Net PPE: 1066.00
GENF.L balance_sheet (annual, 2025-12-31) — Net Tangible Assets: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: -550785.00
GENF.L income_statement (annual, 2025-12-31) — Normalized EBITDA: -1416471.00
GENF.L income_statement (annual, 2025-12-31) — Normalized Income: -1417564.00
GENF.L cash_flow (annual, 2025-12-31) — Operating Cash Flow: -1436585.00
GENF.L income_statement (annual, 2025-12-31) — Operating Income: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Operating Revenue: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 493547942.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 493547942.00
GENF.L balance_sheet (annual, 2025-12-31) — Other Payable: 17299.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Other Payable: 17299.00
GENF.L balance_sheet (annual, 2025-12-31) — Other Receivables: 267325.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Other Receivables: 267325.00
GENF.L income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Payables: 663959.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Payables: 663959.00
GENF.L balance_sheet (annual, 2025-12-31) — Prepaid Assets: 44096.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 44096.00
GENF.L income_statement (annual, 2025-12-31) — Pretax Income: -1417564.00
GENF.L income_statement (annual, 2025-12-31) — Reconciled Depreciation: 1093.00
GENF.L income_statement (annual, 2025-12-31) — Research And Development: 1110486.00
GENF.L balance_sheet (annual, 2025-12-31) — Retained Earnings: -7008664.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -7008664.00
GENF.L income_statement (annual, 2025-12-31) — Selling And Marketing Expense: 92891.00
GENF.L income_statement (annual, 2025-12-31) — Selling General And Administration: 497630.00
GENF.L balance_sheet (annual, 2025-12-31) — Share Issued: 493547942.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Share Issued: 493547942.00
GENF.L cash_flow (annual, 2025-12-31) — Stock Based Compensation: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Stockholders Equity: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: -550785.00
GENF.L balance_sheet (annual, 2025-12-31) — Tangible Book Value: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -550785.00
GENF.L income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
GENF.L income_statement (annual, 2025-12-31) — Tax Provision: 0.00
GENF.L income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
GENF.L balance_sheet (annual, 2025-12-31) — Taxes Receivable: 28107.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 28107.00
GENF.L balance_sheet (annual, 2025-12-31) — Total Assets: 452386.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Total Assets: 452386.00
GENF.L balance_sheet (annual, 2025-12-31) — Total Capitalization: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Total Capitalization: -550785.00
GENF.L balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: -550785.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: -550785.00
GENF.L income_statement (annual, 2025-12-31) — Total Expenses: 1417564.00
GENF.L balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 1003171.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 1003171.00
GENF.L balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 1066.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 1066.00
GENF.L balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
GENF.L income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -1417564.00
GENF.L balance_sheet (annual, 2025-12-31) — Working Capital: -551851.00
GENF.L balance_sheet (quarterly, 2025-12-31) — Working Capital: -551851.00
GENI cash_flow (annual, 2021-12-31) — Cash Dividends Paid: -313162000.00
GENI balance_sheet (annual, 2021-12-31) — Current Debt: 23000.00
GENI balance_sheet (annual, 2021-12-31) — Current Deferred Assets: 0.00
GENI cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: 11412000.00
GENI cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: 0.00
GENI income_statement (annual, 2021-12-31) — Interest Expense: 3331000.00
GENI income_statement (annual, 2021-12-31) — Interest Expense Non Operating: 3331000.00
GENI cash_flow (annual, 2021-12-31) — Issuance Of Debt: 0.00
GENI balance_sheet (annual, 2021-12-31) — Long Term Debt: 65000.00
GENI cash_flow (annual, 2021-12-31) — Long Term Debt Issuance: 0.00
GENI cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: 0.00
GENI cash_flow (annual, 2021-12-31) — Net Other Financing Charges: 231296000.00
GENI cash_flow (annual, 2021-12-31) — Net Preferred Stock Issuance: 0.00
GENI balance_sheet (annual, 2021-12-31) — Non Current Deferred Taxes Assets: 0.00
GENI balance_sheet (annual, 2021-12-31) — Notes Receivable: 0.00
GENI balance_sheet (annual, 2021-12-31) — Other Current Borrowings: 23000.00
GENI balance_sheet (annual, 2021-12-31) — Other Current Liabilities: 38634000.00
GENI balance_sheet (annual, 2021-12-31) — Other Non Current Liabilities: 6532000.00
GENI income_statement (annual, 2021-12-31) — Otherunder Preferred Stock Dividend: 11327000.00
GENI balance_sheet (annual, 2021-12-31) — Preferred Securities Outside Stock Equity: 0.00
GENI cash_flow (annual, 2021-12-31) — Preferred Stock Dividend Paid: -313162000.00
GENI cash_flow (annual, 2021-12-31) — Preferred Stock Issuance: 0.00
GENI cash_flow (annual, 2021-12-31) — Purchase Of Investment: 0.00
GENI income_statement (annual, 2022-12-31) — +Operating Expense: 184067000.00
GENI income_statement (annual, 2022-12-31) — +Total Revenue: 341029000.00
GENI balance_sheet (annual, 2022-12-31) — Accounts Payable: 33121000.00
GENI balance_sheet (annual, 2022-12-31) — Accounts Receivable: 33378000.00
GENI balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -14072000.00
GENI balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 1568917000.00
GENI balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -2486000.00
GENI income_statement (annual, 2022-12-31) — Basic Average Shares: 198939079.00
GENI income_statement (annual, 2022-12-31) — Basic EPS: -0.91
GENI cash_flow (annual, 2022-12-31) — Beginning Cash Position: 222378000.00
GENI balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 2178000.00
GENI cash_flow (annual, 2022-12-31) — Capital Expenditure: -47550000.00
GENI cash_flow (annual, 2022-12-31) — Capital Expenditure Reported: -41387000.00
GENI balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 6746000.00
GENI balance_sheet (annual, 2022-12-31) — Capital Stock: 2021000.00
GENI balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 122715000.00
GENI balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 122715000.00
GENI cash_flow (annual, 2022-12-31) — Cash Dividends Paid: 0.00
GENI cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -21000.00
GENI cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -54821000.00
GENI cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -3455000.00
GENI cash_flow (annual, 2022-12-31) — Change In Account Payable: 15743000.00
GENI cash_flow (annual, 2022-12-31) — Change In Accrued Expense: 7147000.00
GENI cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 2864000.00
GENI cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -4092000.00
GENI cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 14939000.00
GENI cash_flow (annual, 2022-12-31) — Change In Payable: 15743000.00
GENI cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 22890000.00
GENI cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -7120000.00
GENI cash_flow (annual, 2022-12-31) — Change In Receivables: -10695000.00
GENI cash_flow (annual, 2022-12-31) — Change In Working Capital: 18786000.00
GENI cash_flow (annual, 2022-12-31) — Changes In Account Receivables: 8796000.00
GENI cash_flow (annual, 2022-12-31) — Changes In Cash: -58297000.00
GENI balance_sheet (annual, 2022-12-31) — Common Stock: 2021000.00
GENI balance_sheet (annual, 2022-12-31) — Common Stock Equity: 576816000.00
GENI cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
GENI income_statement (annual, 2022-12-31) — Cost Of Revenue: 338166000.00
GENI balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 56956000.00
GENI balance_sheet (annual, 2022-12-31) — Current Assets: 236517000.00
GENI balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 3462000.00
GENI balance_sheet (annual, 2022-12-31) — Current Debt: 7405000.00
GENI balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 10867000.00
GENI balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 48878000.00
GENI balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 41273000.00
GENI balance_sheet (annual, 2022-12-31) — Current Liabilities: 171140000.00
GENI cash_flow (annual, 2022-12-31) — Deferred Income Tax: -113000.00
GENI cash_flow (annual, 2022-12-31) — Deferred Tax: -113000.00
GENI cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 68529000.00
GENI cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 68529000.00
GENI income_statement (annual, 2022-12-31) — Diluted Average Shares: 198939079.00
GENI income_statement (annual, 2022-12-31) — Diluted EPS: -0.91
GENI income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -181636000.00
GENI cash_flow (annual, 2022-12-31) — Dividends Received Cfi: -7871000.00
GENI income_statement (annual, 2022-12-31) — EBIT: -181204000.00
GENI income_statement (annual, 2022-12-31) — EBITDA: -112675000.00
GENI income_statement (annual, 2022-12-31) — Earnings From Equity Interest Net Of Tax: 3358000.00
GENI cash_flow (annual, 2022-12-31) — Earnings Losses From Equity Investments: -3358000.00
GENI cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -5061000.00
GENI cash_flow (annual, 2022-12-31) — End Cash Position: 159020000.00
GENI cash_flow (annual, 2022-12-31) — Financing Cash Flow: -21000.00
GENI cash_flow (annual, 2022-12-31) — Free Cash Flow: -51005000.00
GENI cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -10132000.00
GENI cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 281000.00
GENI income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: -292000.00
GENI income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 1153000.00
GENI balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -55169000.00
GENI income_statement (annual, 2022-12-31) — General And Administrative Expense: 122829000.00
GENI balance_sheet (annual, 2022-12-31) — Goodwill: 309894000.00
GENI balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 459142000.00
GENI balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 35864000.00
GENI balance_sheet (annual, 2022-12-31) — Gross PPE: 33412000.00
GENI income_statement (annual, 2022-12-31) — Gross Profit: 2863000.00
GENI cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 2054000.00
GENI income_statement (annual, 2022-12-31) — Interest Expense: 1487000.00
GENI income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 1487000.00
GENI cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 798000.00
GENI balance_sheet (annual, 2022-12-31) — Inventory: 283000.00
GENI balance_sheet (annual, 2022-12-31) — Invested Capital: 591309000.00
GENI cash_flow (annual, 2022-12-31) — Investing Cash Flow: -54821000.00
GENI balance_sheet (annual, 2022-12-31) — Investments And Advances: 23682000.00
GENI cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
GENI cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
GENI balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 3284000.00
GENI balance_sheet (annual, 2022-12-31) — Long Term Debt: 7088000.00
GENI balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 10372000.00
GENI cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
GENI cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -21000.00
GENI balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 23682000.00
GENI balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 24741000.00
GENI cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -20000.00
GENI cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
GENI cash_flow (annual, 2022-12-31) — Net Foreign Currency Exchange Gain Loss: 5577000.00
GENI income_statement (annual, 2022-12-31) — Net Income: -181636000.00
GENI income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -181636000.00
GENI income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -181636000.00
GENI income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -181636000.00
GENI income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -181636000.00
GENI cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -181636000.00
GENI income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -181636000.00
GENI cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -196000.00
GENI income_statement (annual, 2022-12-31) — Net Interest Income: -1487000.00
GENI cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -150000.00
GENI cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -21000.00
GENI cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -21000.00
GENI income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -1487000.00
GENI cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 770000.00
GENI balance_sheet (annual, 2022-12-31) — Net PPE: 19340000.00
GENI cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -5967000.00
GENI cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 0.00
GENI balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 117674000.00
GENI balance_sheet (annual, 2022-12-31) — Non Current Accounts Receivable: 7251000.00
GENI balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 1838000.00
GENI balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 15009000.00
GENI balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 15009000.00
GENI balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 1364000.00
GENI income_statement (annual, 2022-12-31) — Normalized EBITDA: -112086000.00
GENI income_statement (annual, 2022-12-31) — Normalized Income: -181170690.00
GENI cash_flow (annual, 2022-12-31) — Operating Cash Flow: -3455000.00
GENI cash_flow (annual, 2022-12-31) — Operating Gains Losses: -7621000.00
GENI income_statement (annual, 2022-12-31) — Operating Income: -181204000.00
GENI income_statement (annual, 2022-12-31) — Operating Revenue: 341029000.00
GENI balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 205837194.00
GENI balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 7405000.00
GENI balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 17651000.00
GENI balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -55169000.00
GENI income_statement (annual, 2022-12-31) — Other Gand A: 122829000.00
GENI income_statement (annual, 2022-12-31) — Other Income Expense: -589000.00
GENI balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 149248000.00
GENI cash_flow (annual, 2022-12-31) — Other Non Cash Items: 6575000.00
GENI balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 24203000.00
GENI balance_sheet (annual, 2022-12-31) — Other Payable: 3667000.00
GENI balance_sheet (annual, 2022-12-31) — Other Properties: 6493000.00
GENI balance_sheet (annual, 2022-12-31) — Other Receivables: 39832000.00
GENI income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENI balance_sheet (annual, 2022-12-31) — Payables: 36788000.00
GENI balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 93744000.00
GENI balance_sheet (annual, 2022-12-31) — Prepaid Assets: 28207000.00
GENI income_statement (annual, 2022-12-31) — Pretax Income: -183280000.00
GENI cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 0.00
GENI balance_sheet (annual, 2022-12-31) — Properties: 0.00
GENI cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 2186000.00
GENI cash_flow (annual, 2022-12-31) — Purchase Of Business: -20000.00
GENI cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -196000.00
GENI cash_flow (annual, 2022-12-31) — Purchase Of Investment: -150000.00
GENI cash_flow (annual, 2022-12-31) — Purchase Of PPE: -5967000.00
GENI balance_sheet (annual, 2022-12-31) — Receivables: 73210000.00
GENI income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 338166000.00
GENI income_statement (annual, 2022-12-31) — Reconciled Depreciation: 68529000.00
GENI cash_flow (annual, 2022-12-31) — Repayment Of Debt: -21000.00
GENI income_statement (annual, 2022-12-31) — Research And Development: 29894000.00
GENI balance_sheet (annual, 2022-12-31) — Restricted Cash: 12102000.00
GENI income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 1450000.00
GENI balance_sheet (annual, 2022-12-31) — Retained Earnings: -938953000.00
GENI income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 31344000.00
GENI income_statement (annual, 2022-12-31) — Selling General And Administration: 154173000.00
GENI balance_sheet (annual, 2022-12-31) — Share Issued: 205837194.00
GENI cash_flow (annual, 2022-12-31) — Short Term Debt Payments: 0.00
GENI income_statement (annual, 2022-12-31) — Special Income Charges: -1742000.00
GENI cash_flow (annual, 2022-12-31) — Stock Based Compensation: 89839000.00
GENI balance_sheet (annual, 2022-12-31) — Stockholders Equity: 576816000.00
GENI balance_sheet (annual, 2022-12-31) — Tangible Book Value: 117674000.00
GENI income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -123690.00
GENI income_statement (annual, 2022-12-31) — Tax Provision: 1714000.00
GENI income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.21
GENI balance_sheet (annual, 2022-12-31) — Taxes Receivable: 0.00
GENI balance_sheet (annual, 2022-12-31) — Total Assets: 773337000.00
GENI balance_sheet (annual, 2022-12-31) — Total Capitalization: 583904000.00
GENI balance_sheet (annual, 2022-12-31) — Total Debt: 21239000.00
GENI balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 576816000.00
GENI income_statement (annual, 2022-12-31) — Total Expenses: 522233000.00
GENI balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 196521000.00
GENI balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 536820000.00
GENI balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 25381000.00
GENI income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -182872000.00
GENI income_statement (annual, 2022-12-31) — Total Other Finance Cost: 1487000.00
GENI income_statement (annual, 2022-12-31) — Total Unusual Items: -589000.00
GENI income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -589000.00
GENI balance_sheet (annual, 2022-12-31) — Treasury Stock: 0.00
GENI balance_sheet (annual, 2022-12-31) — Working Capital: 65377000.00
GENI income_statement (annual, 2023-12-31) — +Operating Expense: 140669000.00
GENI income_statement (annual, 2023-12-31) — +Total Revenue: 412977000.00
GENI balance_sheet (annual, 2023-12-31) — Accounts Payable: 57379000.00
GENI balance_sheet (annual, 2023-12-31) — Accounts Receivable: 71088000.00
GENI balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -19265000.00
GENI balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 1646082000.00
GENI balance_sheet (annual, 2023-12-31) — Allowance For Doubtful Accounts Receivable: -5136000.00
GENI income_statement (annual, 2023-12-31) — Basic Average Shares: 225882254.00
GENI income_statement (annual, 2023-12-31) — Basic EPS: -0.38
GENI cash_flow (annual, 2023-12-31) — Beginning Cash Position: 159020000.00
GENI balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 1927000.00
GENI cash_flow (annual, 2023-12-31) — Capital Expenditure: -49143000.00
GENI cash_flow (annual, 2023-12-31) — Capital Expenditure Reported: -44158000.00
GENI balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 7111000.00
GENI balance_sheet (annual, 2023-12-31) — Capital Stock: 2134000.00
GENI balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 100331000.00
GENI balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 100331000.00
GENI cash_flow (annual, 2023-12-31) — Cash Dividends Paid: 0.00
GENI cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -596000.00
GENI cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -47570000.00
GENI cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 14876000.00
GENI cash_flow (annual, 2023-12-31) — Change In Account Payable: 22065000.00
GENI cash_flow (annual, 2023-12-31) — Change In Accrued Expense: -3513000.00
GENI cash_flow (annual, 2023-12-31) — Change In Other Current Assets: -339000.00
GENI cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -4692000.00
GENI cash_flow (annual, 2023-12-31) — Change In Other Working Capital: 906000.00
GENI cash_flow (annual, 2023-12-31) — Change In Payable: 22065000.00
GENI cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 18552000.00
GENI cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -8643000.00
GENI cash_flow (annual, 2023-12-31) — Change In Receivables: -30879000.00
GENI cash_flow (annual, 2023-12-31) — Change In Working Capital: -25095000.00
GENI cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -32489000.00
GENI cash_flow (annual, 2023-12-31) — Changes In Cash: -33290000.00
GENI balance_sheet (annual, 2023-12-31) — Common Stock: 2134000.00
GENI balance_sheet (annual, 2023-12-31) — Common Stock Equity: 573019000.00
GENI cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
GENI income_statement (annual, 2023-12-31) — Cost Of Revenue: 343972000.00
GENI balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 56331000.00
GENI balance_sheet (annual, 2023-12-31) — Current Assets: 244781000.00
GENI balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 3610000.00
GENI balance_sheet (annual, 2023-12-31) — Current Debt: 7573000.00
GENI balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 11183000.00
GENI balance_sheet (annual, 2023-12-31) — Current Deferred Assets: 0.00
GENI balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 50546000.00
GENI balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 44345000.00
GENI balance_sheet (annual, 2023-12-31) — Current Liabilities: 182914000.00
GENI cash_flow (annual, 2023-12-31) — Deferred Income Tax: -444000.00
GENI cash_flow (annual, 2023-12-31) — Deferred Tax: -444000.00
GENI cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 77308000.00
GENI cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 77308000.00
GENI income_statement (annual, 2023-12-31) — Diluted Average Shares: 225882254.00
GENI income_statement (annual, 2023-12-31) — Diluted EPS: -0.38
GENI income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -85534000.00
GENI cash_flow (annual, 2023-12-31) — Dividends Received Cfi: 1555000.00
GENI income_statement (annual, 2023-12-31) — EBIT: -71664000.00
GENI income_statement (annual, 2023-12-31) — EBITDA: 5644000.00
GENI income_statement (annual, 2023-12-31) — Earnings From Equity Interest Net Of Tax: 3106000.00
GENI cash_flow (annual, 2023-12-31) — Earnings Losses From Equity Investments: -3106000.00
GENI cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 63000.00
GENI cash_flow (annual, 2023-12-31) — End Cash Position: 125793000.00
GENI cash_flow (annual, 2023-12-31) — Financing Cash Flow: -596000.00
GENI cash_flow (annual, 2023-12-31) — Free Cash Flow: -34267000.00
GENI cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: 534000.00
GENI cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 0.00
GENI income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: -11517000.00
GENI income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 3341000.00
GENI balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -33057000.00
GENI income_statement (annual, 2023-12-31) — General And Administrative Expense: 85167000.00
GENI balance_sheet (annual, 2023-12-31) — Goodwill: 326011000.00
GENI balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 455681000.00
GENI balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 76224000.00
GENI balance_sheet (annual, 2023-12-31) — Gross PPE: 37828000.00
GENI income_statement (annual, 2023-12-31) — Gross Profit: 69005000.00
GENI cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 4490000.00
GENI balance_sheet (annual, 2023-12-31) — Income Tax Payable: 1800000.00
GENI income_statement (annual, 2023-12-31) — Interest Income: 1953000.00
GENI income_statement (annual, 2023-12-31) — Interest Income Non Operating: 1953000.00
GENI cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 8000.00
GENI balance_sheet (annual, 2023-12-31) — Inventory: 347000.00
GENI balance_sheet (annual, 2023-12-31) — Invested Capital: 580611000.00
GENI cash_flow (annual, 2023-12-31) — Investing Cash Flow: -47570000.00
GENI balance_sheet (annual, 2023-12-31) — Investments And Advances: 26399000.00
GENI cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
GENI balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 3501000.00
GENI balance_sheet (annual, 2023-12-31) — Long Term Debt: 19000.00
GENI balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 3520000.00
GENI cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -21000.00
GENI balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 26399000.00
GENI balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 18018000.00
GENI cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
GENI cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 0.00
GENI cash_flow (annual, 2023-12-31) — Net Foreign Currency Exchange Gain Loss: -5571000.00
GENI income_statement (annual, 2023-12-31) — Net Income: -85534000.00
GENI income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -85534000.00
GENI income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -85534000.00
GENI income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -85534000.00
GENI income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -85534000.00
GENI cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -85534000.00
GENI income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -85534000.00
GENI cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -1416000.00
GENI income_statement (annual, 2023-12-31) — Net Interest Income: 1953000.00
GENI cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 0.00
GENI cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -7408000.00
GENI cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -21000.00
GENI income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: 1953000.00
GENI cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 18000.00
GENI balance_sheet (annual, 2023-12-31) — Net PPE: 18563000.00
GENI cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -3569000.00
GENI cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: -7387000.00
GENI balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 117338000.00
GENI balance_sheet (annual, 2023-12-31) — Non Current Accounts Receivable: 1501000.00
GENI balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 1973000.00
GENI balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 15851000.00
GENI balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 0.00
GENI balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 15335000.00
GENI balance_sheet (annual, 2023-12-31) — Non Current Prepaid Assets: 1364000.00
GENI income_statement (annual, 2023-12-31) — Normalized EBITDA: 19233000.00
GENI income_statement (annual, 2023-12-31) — Normalized Income: -74798690.00
GENI cash_flow (annual, 2023-12-31) — Operating Cash Flow: 14876000.00
GENI cash_flow (annual, 2023-12-31) — Operating Gains Losses: 3374000.00
GENI income_statement (annual, 2023-12-31) — Operating Income: -71664000.00
GENI income_statement (annual, 2023-12-31) — Operating Revenue: 412977000.00
GENI balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 209118920.00
GENI balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 7573000.00
GENI balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 4434000.00
GENI balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -33057000.00
GENI income_statement (annual, 2023-12-31) — Other Gand A: 85167000.00
GENI income_statement (annual, 2023-12-31) — Other Income Expense: -13589000.00
GENI balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 129670000.00
GENI cash_flow (annual, 2023-12-31) — Other Non Cash Items: 7431000.00
GENI balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 25462000.00
GENI balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 420000.00
GENI balance_sheet (annual, 2023-12-31) — Other Payable: 1241000.00
GENI balance_sheet (annual, 2023-12-31) — Other Properties: 17883000.00
GENI balance_sheet (annual, 2023-12-31) — Other Receivables: 39029000.00
GENI income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
GENI balance_sheet (annual, 2023-12-31) — Payables: 60420000.00
GENI balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 116751000.00
GENI balance_sheet (annual, 2023-12-31) — Prepaid Assets: 27231000.00
GENI income_statement (annual, 2023-12-31) — Pretax Income: -83300000.00
GENI cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 6812000.00
GENI balance_sheet (annual, 2023-12-31) — Properties: 0.00
GENI cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 2518000.00
GENI cash_flow (annual, 2023-12-31) — Purchase Of Business: 0.00
GENI cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -1416000.00
GENI cash_flow (annual, 2023-12-31) — Purchase Of Investment: 0.00
GENI cash_flow (annual, 2023-12-31) — Purchase Of PPE: -3569000.00
GENI balance_sheet (annual, 2023-12-31) — Receivables: 116872000.00
GENI income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 343972000.00
GENI income_statement (annual, 2023-12-31) — Reconciled Depreciation: 77308000.00
GENI cash_flow (annual, 2023-12-31) — Repayment Of Debt: -7408000.00
GENI income_statement (annual, 2023-12-31) — Research And Development: 26070000.00
GENI balance_sheet (annual, 2023-12-31) — Restricted Cash: 0.00
GENI income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 5413000.00
GENI balance_sheet (annual, 2023-12-31) — Retained Earnings: -1024487000.00
GENI cash_flow (annual, 2023-12-31) — Sale Of Business: 1555000.00
GENI income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 29432000.00
GENI income_statement (annual, 2023-12-31) — Selling General And Administration: 114599000.00
GENI balance_sheet (annual, 2023-12-31) — Share Issued: 213224868.00
GENI cash_flow (annual, 2023-12-31) — Short Term Debt Payments: -7387000.00
GENI income_statement (annual, 2023-12-31) — Special Income Charges: -16930000.00
GENI cash_flow (annual, 2023-12-31) — Stock Based Compensation: 35318000.00
GENI balance_sheet (annual, 2023-12-31) — Stockholders Equity: 573019000.00
GENI balance_sheet (annual, 2023-12-31) — Tangible Book Value: 117338000.00
GENI income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -2853690.00
GENI income_statement (annual, 2023-12-31) — Tax Provision: 5340000.00
GENI income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.21
GENI balance_sheet (annual, 2023-12-31) — Taxes Receivable: 6755000.00
GENI balance_sheet (annual, 2023-12-31) — Total Assets: 775724000.00
GENI balance_sheet (annual, 2023-12-31) — Total Capitalization: 573038000.00
GENI balance_sheet (annual, 2023-12-31) — Total Debt: 14703000.00
GENI balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 573019000.00
GENI income_statement (annual, 2023-12-31) — Total Expenses: 484641000.00
GENI balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 202705000.00
GENI balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 530943000.00
GENI balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 19791000.00
GENI income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -74158000.00
GENI income_statement (annual, 2023-12-31) — Total Other Finance Cost: -1953000.00
GENI balance_sheet (annual, 2023-12-31) — Total Tax Payable: 1800000.00
GENI income_statement (annual, 2023-12-31) — Total Unusual Items: -13589000.00
GENI income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -13589000.00
GENI balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 4105948.00
GENI balance_sheet (annual, 2023-12-31) — Treasury Stock: 17653000.00
GENI balance_sheet (annual, 2023-12-31) — Working Capital: 61867000.00
GENI balance_sheet (quarterly, 2024-09-30) — Current Debt: 23000.00
GENI balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 4000.00
GENI cash_flow (quarterly, 2024-09-30) — Long Term Debt Payments: -7000.00
GENI cash_flow (quarterly, 2024-09-30) — Net Long Term Debt Issuance: -7000.00
GENI balance_sheet (quarterly, 2024-09-30) — Other Current Borrowings: 23000.00
GENI balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 4685000.00
GENI cash_flow (quarterly, 2024-09-30) — Proceeds From Stock Option Exercised: 0.00
GENI income_statement (quarterly, 2024-09-30) — Total Other Finance Cost: 13000.00
GENI income_statement (annual, 2024-12-31) — +Operating Expense: 184998000.00
GENI income_statement (annual, 2024-12-31) — +Total Revenue: 510894000.00
GENI balance_sheet (annual, 2024-12-31) — Accounts Payable: 36661000.00
GENI balance_sheet (annual, 2024-12-31) — Accounts Receivable: 85491000.00
GENI balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -20016000.00
GENI balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -20016000.00
GENI balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 1700065000.00
GENI balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -4974000.00
GENI income_statement (annual, 2024-12-31) — Basic Average Shares: 229509169.00
GENI income_statement (annual, 2024-12-31) — Basic EPS: -0.27
GENI cash_flow (annual, 2024-12-31) — Beginning Cash Position: 125793000.00
GENI balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 1901000.00
GENI balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 1901000.00
GENI cash_flow (annual, 2024-12-31) — Capital Expenditure: -64256000.00
GENI cash_flow (annual, 2024-12-31) — Capital Expenditure Reported: -51963000.00
GENI balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 7492000.00
GENI balance_sheet (annual, 2024-12-31) — Capital Stock: 2155000.00
GENI balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 110213000.00
GENI balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 110213000.00
GENI cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -7597000.00
GENI cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -62685000.00
GENI cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 81861000.00
GENI cash_flow (annual, 2024-12-31) — Change In Account Payable: -20718000.00
GENI cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 22841000.00
GENI cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -1768000.00
GENI cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -9454000.00
GENI cash_flow (annual, 2024-12-31) — Change In Other Working Capital: 27603000.00
GENI cash_flow (annual, 2024-12-31) — Change In Payable: -20718000.00
GENI cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 2123000.00
GENI cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: -101000.00
GENI cash_flow (annual, 2024-12-31) — Change In Receivables: -7690000.00
GENI cash_flow (annual, 2024-12-31) — Change In Working Capital: 10713000.00
GENI cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -15860000.00
GENI cash_flow (annual, 2024-12-31) — Changes In Cash: 11579000.00
GENI balance_sheet (annual, 2024-12-31) — Common Stock: 2155000.00
GENI balance_sheet (annual, 2024-12-31) — Common Stock Equity: 572405000.00
GENI cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
GENI income_statement (annual, 2024-12-31) — Cost Of Revenue: 382187000.00
GENI balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 79172000.00
GENI balance_sheet (annual, 2024-12-31) — Current Assets: 288597000.00
GENI balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 3003000.00
GENI balance_sheet (annual, 2024-12-31) — Current Debt: 19000.00
GENI balance_sheet (quarterly, 2024-12-31) — Current Debt: 19000.00
GENI balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 3022000.00
GENI balance_sheet (annual, 2024-12-31) — Current Deferred Assets: 1104000.00
GENI balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 79419000.00
GENI balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 73388000.00
GENI balance_sheet (annual, 2024-12-31) — Current Liabilities: 201570000.00
GENI cash_flow (annual, 2024-12-31) — Deferred Income Tax: -2724000.00
GENI cash_flow (annual, 2024-12-31) — Deferred Tax: -2724000.00
GENI cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 72572000.00
GENI cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 72572000.00
GENI income_statement (annual, 2024-12-31) — Diluted Average Shares: 229509169.00
GENI income_statement (annual, 2024-12-31) — Diluted EPS: -0.27
GENI income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -63040000.00
GENI cash_flow (annual, 2024-12-31) — Dividends Received Cfi: 1561000.00
GENI income_statement (annual, 2024-12-31) — EBIT: -56291000.00
GENI income_statement (annual, 2024-12-31) — EBITDA: 16281000.00
GENI income_statement (annual, 2024-12-31) — Earnings From Equity Interest Net Of Tax: 3727000.00
GENI cash_flow (annual, 2024-12-31) — Earnings Losses From Equity Investments: -3727000.00
GENI cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -2133000.00
GENI cash_flow (annual, 2024-12-31) — End Cash Position: 135239000.00
GENI cash_flow (annual, 2024-12-31) — Financing Cash Flow: -7597000.00
GENI cash_flow (annual, 2024-12-31) — Free Cash Flow: 17605000.00